Sierra Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Sierra Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5	Closed	-$4K	–	476
2022 Q4	$4K	Hold	5	–	–	﹤0.01%	436
2022 Q3	$3K	Hold	5	–	–	﹤0.01%	479
2022 Q2	$3K	Sell	5 -77	-94%	-$50.1K	﹤0.01%	545
2022 Q1	$57K	Sell	82 -1	-1%	-$633	0.01%	335
2021 Q4	$52K	Buy	83 +6	+8%	+$3.69K	0.01%	340
2021 Q3	$47K	Hold	77	–	–	0.01%	308
2021 Q2	$43K	Hold	77	–	–	0.01%	297
2021 Q1	$36K	Buy	+77	New	+$37.5K	0.01%	292

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sierra Capital's REGN Position: Q1 2023 in Review

Sierra Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 5 shares — an estimated $4K sold.

Sierra Capital first reported a position in REGN in Q1 2021 and held it in 8 quarters. The position peaked at $57K in Q1 2022. 1,191 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

Sierra Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Sierra Capital sold 5 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $4K.
Sierra Capital first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 8 quarters.
Sierra Capital's Regeneron Pharmaceuticals position peaked at $57K in Q1 2022.
1,191 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Sierra Capital's 13F filing for Q1 2023, filed 1 May 2023.